Testosterone plus lifestyle outperforms GLP-1 therapy in obesity-linked hypogonadism analysis

A network meta-analysis published in The Journal of Sexual Medicine compared five treatment strategies for obesity-related functional hypogonadism in men and found that testosterone replacement combined with structured lifestyle therapy produced the largest rise in testosterone and was the only approach that significantly improved erectile function scores ^[1][2].

The review pooled 23 randomized controlled trials involving 1,899 men. Researchers searched PubMed, Embase, Web of Science and the Cochrane Library from their start through April 2026 ^[2]. The paper describes functional hypogonadism as a potentially reversible condition tied to sexual dysfunction, metabolic disorders, altered body composition and reduced quality of life ^[2].

The strategies compared were structured lifestyle therapy alone, testosterone replacement therapy (TRT), a category the paper labels endogenous testosterone restoration (ETR) therapy, GLP-1 receptor agonist-based therapy, and TRT plus structured lifestyle therapy ^[2].

Compared with usual care or placebo, TRT plus structured lifestyle therapy showed the largest estimated increase in total testosterone, a mean difference of 7.19 (95% CI 1.18 to 13.21). ETR therapy followed at 4.14 (95% CI 0.74 to 7.54), then TRT alone at 2.53 (95% CI 0.26 to 4.81) ^[2].

Only TRT plus structured lifestyle therapy significantly improved International Index of Erectile Function scores, with a mean difference of 1.29 (95% CI 0.07 to 2.50) ^[2].

GLP-1 receptor agonist-based therapy was part of the comparison network but did not post the largest testosterone increase or the erectile function result ^[2]. The published summary does not give a separate effect estimate for GLP-1-based therapy, and it does not name the specific GLP-1 drugs the trials used, so which medicines were studied and at what doses has not been disclosed ^[2].

Other results

No intervention significantly reduced glycated hemoglobin, a marker of average blood sugar, compared with usual care or placebo ^[2].

TRT reduced waist circumference and increased lean mass, but it also increased hematocrit, which reflects the concentration of red blood cells in blood. ETR therapy and TRT plus structured lifestyle therapy also increased lean mass ^[2].

The authors detected no significant differences in adverse events across the strategies ^[2].

Confidence in many of the comparisons was rated low or very low, and the included trials differed in participant characteristics, treatment protocols and follow-up length. Sensitivity analyses and direct-evidence analyses generally supported the direction of the main findings ^[2].

The paper's discussion states that no single strategy was consistently superior across all outcomes, that the results should inform individualized treatment decisions rather than a definitive ranking, and that longer-term head-to-head trials are needed ^[2].

Why it matters for patients

For men considering treatment for obesity-related low testosterone, this analysis does not place GLP-1-based therapy at the top of the network for either hormone levels or erectile function. Testosterone-containing strategies held those positions ^[2].

The paper does not report how GLP-1 therapy performed against usual care on those specific measures, so this is not a finding that GLP-1 drugs failed. It is a finding that they were not the leading strategy in this comparison ^[2].

The results also cannot be mapped onto a specific prescription. The trials are described only as using GLP-1 receptor agonist-based therapy as a class, so whether semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) was used has not been reported ^[2].

The authors' low confidence ratings matter for anyone reading the ranking as a final answer. The analysis mixes trials with different patients, protocols and follow-up periods, and its authors write that longer-term head-to-head studies are needed to confirm the findings ^[2].

The trade-offs are also worth noting. TRT raised hematocrit in this analysis even as it lowered waist circumference and raised lean mass, and no strategy significantly lowered glycated hemoglobin ^[2]. Whether any of these strategies change long-term health outcomes, such as heart events or deaths, has not been reported ^[2].